Reported Earnings • Apr 21
Full year 2025 earnings released: EPS: CA$0.30 (vs CA$0.19 in FY 2024) Full year 2025 results: EPS: CA$0.30 (up from CA$0.19 in FY 2024). Revenue: CA$42.4m (up 13% from FY 2024). Net income: CA$4.82m (up 58% from FY 2024). Profit margin: 11% (up from 8.1% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CA$2.97, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 33x in the Commercial Services industry in Canada. Total returns to shareholders of 178% over the past three years. Annonce • Apr 14
BioRem Inc., Annual General Meeting, Jun 03, 2026 BioRem Inc., Annual General Meeting, Jun 03, 2026. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CA$2.79, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Commercial Services industry in Canada. Total returns to shareholders of 166% over the past three years. Valuation Update With 7 Day Price Move • Nov 26
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CA$2.76, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Commercial Services industry in Canada. Total returns to shareholders of 229% over the past three years. Reported Earnings • Nov 19
Third quarter 2025 earnings released: EPS: CA$0.072 (vs CA$0.14 in 3Q 2024) Third quarter 2025 results: EPS: CA$0.072 (down from CA$0.14 in 3Q 2024). Revenue: CA$11.3m (down 24% from 3Q 2024). Net income: CA$1.16m (down 47% from 3Q 2024). Profit margin: 10% (down from 15% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 1.5% decline forecast for the Commercial Services industry in Canada. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 26
Second quarter 2025 earnings released: EPS: CA$0.046 (vs CA$0.022 in 2Q 2024) Second quarter 2025 results: EPS: CA$0.046 (up from CA$0.022 in 2Q 2024). Revenue: CA$9.43m (up 29% from 2Q 2024). Net income: CA$744.8k (up 119% from 2Q 2024). Profit margin: 7.9% (up from 4.7% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, while revenues in the Commercial Services industry in Canada are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 38% per year and the company’s share price has also increased by 38% per year. Valuation Update With 7 Day Price Move • Aug 25
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CA$2.33, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 14x in the Commercial Services industry in Canada. Total returns to shareholders of 174% over the past three years. Reported Earnings • May 29
First quarter 2025 earnings released: EPS: CA$0.002 (vs CA$0.022 in 1Q 2024) First quarter 2025 results: EPS: CA$0.002 (down from CA$0.022 in 1Q 2024). Revenue: CA$4.73m (down 20% from 1Q 2024). Net income: CA$37.2k (down 89% from 1Q 2024). Profit margin: 0.8% (down from 5.8% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 2.2% decline forecast for the Commercial Services industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 14
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CA$2.18, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 11x in the Commercial Services industry in Canada. Total returns to shareholders of 207% over the past three years. Reported Earnings • Apr 16
Full year 2024 earnings released: EPS: CA$0.19 (vs CA$0.14 in FY 2023) Full year 2024 results: EPS: CA$0.19 (up from CA$0.14 in FY 2023). Revenue: CA$37.4m (up 49% from FY 2023). Net income: CA$3.04m (up 40% from FY 2023). Profit margin: 8.1% (down from 8.7% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Annonce • Apr 09
BioRem Inc., Annual General Meeting, Jun 03, 2025 BioRem Inc., Annual General Meeting, Jun 03, 2025. Recent Insider Transactions • Dec 05
CEO, President & Director recently sold CA$352k worth of stock On the 2nd of December, Derek Webb sold around 120k shares on-market at roughly CA$2.93 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Derek's only on-market trade for the last 12 months. New Risk • Nov 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (CA$48.5m market cap, or US$34.6m). Valuation Update With 7 Day Price Move • Nov 13
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to CA$3.13, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 27x in the Commercial Services industry in Canada. Total returns to shareholders of 260% over the past three years. Reported Earnings • Nov 07
Third quarter 2024 earnings released: EPS: CA$0.14 (vs CA$0.032 in 3Q 2023) Third quarter 2024 results: EPS: CA$0.14 (up from CA$0.032 in 3Q 2023). Revenue: CA$14.9m (up 170% from 3Q 2023). Net income: CA$2.19m (up 336% from 3Q 2023). Profit margin: 15% (up from 9.1% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 27
Second quarter 2024 earnings released: EPS: CA$0.021 (vs CA$0.006 loss in 2Q 2023) Second quarter 2024 results: EPS: CA$0.021 (up from CA$0.006 loss in 2Q 2023). Revenue: CA$7.30m (up 71% from 2Q 2023). Net income: CA$339.8k (up CA$436.3k from 2Q 2023). Profit margin: 4.7% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year whereas the company’s share price has increased by 55% per year. Reported Earnings • May 29
First quarter 2024 earnings released: EPS: CA$0.022 (vs CA$0.036 loss in 1Q 2023) First quarter 2024 results: EPS: CA$0.022 (up from CA$0.036 loss in 1Q 2023). Revenue: CA$5.92m (up 87% from 1Q 2023). Net income: CA$344.1k (up CA$901.6k from 1Q 2023). Profit margin: 5.8% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth. Annonce • Apr 13
BioRem Inc., Annual General Meeting, Jun 04, 2024 BioRem Inc., Annual General Meeting, Jun 04, 2024. Reported Earnings • Apr 11
Full year 2023 earnings released: EPS: CA$0.14 (vs CA$0.10 in FY 2022) Full year 2023 results: EPS: CA$0.14 (up from CA$0.10 in FY 2022). Revenue: CA$25.2m (down 13% from FY 2022). Net income: CA$2.18m (up 35% from FY 2022). Profit margin: 8.7% (up from 5.6% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment improves as stock rises 39% After last week's 39% share price gain to CA$1.40, the stock trades at a trailing P/E ratio of 34.3x. Average trailing P/E is 24x in the Commercial Services industry in Canada. Total returns to shareholders of 119% over the past three years. Reported Earnings • Dec 01
Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.049 in 3Q 2022) Third quarter 2023 results: EPS: CA$0.03 (down from CA$0.049 in 3Q 2022). Revenue: CA$5.51m (down 25% from 3Q 2022). Net income: CA$503.1k (down 34% from 3Q 2022). Profit margin: 9.1% (down from 10% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth. Board Change • Sep 12
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Chairman of the Board Bill White was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Aug 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 17% per year over the past 5 years. High level of non-cash earnings (54% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Profit margins are more than 30% lower than last year (3.5% net profit margin). Market cap is less than US$100m (CA$16.3m market cap, or US$12.0m). Reported Earnings • Aug 24
Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.011 profit in 2Q 2022) Second quarter 2023 results: CA$0.006 loss per share (down from CA$0.011 profit in 2Q 2022). Revenue: CA$4.28m (down 32% from 2Q 2022). Net loss: CA$96.5k (down 159% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth. Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Chairman of the Board Bill White was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jun 07
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CA$1.01, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 25x in the Commercial Services industry in Canada. Total returns to shareholders of 221% over the past three years. Reported Earnings • May 26
First quarter 2023 earnings released: CA$0.036 loss per share (vs CA$0.007 loss in 1Q 2022) First quarter 2023 results: CA$0.036 loss per share (further deteriorated from CA$0.007 loss in 1Q 2022). Revenue: CA$3.17m (down 28% from 1Q 2022). Net loss: CA$557.5k (loss widened 452% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 06
Full year 2022 earnings released: EPS: CA$0.10 (vs CA$0.036 in FY 2021) Full year 2022 results: EPS: CA$0.10 (up from CA$0.036 in FY 2021). Revenue: CA$28.9m (up 18% from FY 2021). Net income: CA$1.61m (up 24% from FY 2021). Profit margin: 5.6% (up from 5.3% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 16
Third quarter 2022 earnings released: EPS: CA$0.05 (vs CA$0.003 loss in 3Q 2021) Third quarter 2022 results: EPS: CA$0.05 (up from CA$0.003 loss in 3Q 2021). Revenue: CA$7.31m (up 60% from 3Q 2021). Net income: CA$761.2k (up CA$876.6k from 3Q 2021). Profit margin: 10% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year whereas the company’s share price has increased by 40% per year. Reported Earnings • Aug 24
Second quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.007 in 2Q 2021) Second quarter 2022 results: EPS: CA$0.011. Revenue: CA$6.26m (up 11% from 2Q 2021). Net income: CA$164.3k (down 38% from 2Q 2021). Profit margin: 2.6% (down from 4.7% in 2Q 2021). The decrease in margin was driven by higher expenses. Reported Earnings • May 26
First quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.011 loss in 1Q 2021) First quarter 2022 results: CA$0.007 loss per share (up from CA$0.011 loss in 1Q 2021). Revenue: CA$4.38m (up 28% from 1Q 2021). Net loss: CA$101.0k (loss narrowed 76% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Annonce • Apr 09
BIOREM Inc., Annual General Meeting, Jun 14, 2022 BIOREM Inc., Annual General Meeting, Jun 14, 2022. Reported Earnings • Mar 30
Full year 2021 earnings released: EPS: CA$0.036 (vs CA$0.054 in FY 2020) Full year 2021 results: EPS: CA$0.036 (down from CA$0.054 in FY 2020). Revenue: CA$24.5m (flat on FY 2020). Net income: CA$1.30m (down 38% from FY 2020). Profit margin: 5.3% (down from 8.6% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings. Reported Earnings • Nov 26
Third quarter 2021 earnings: Revenues in line with analyst expectations Third quarter 2021 results: Revenue: CA$4.58m (up 28% from 3Q 2020). Net loss: CA$115.4k (down 174% from profit in 3Q 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings. Annonce • Aug 06
BIOREM Inc. (TSXV:BRM) announces an Equity Buyback for 23,434,121 shares, for CAD 12.32 million. BIOREM Inc. (TSXV:BRM) announces a share repurchase program. Under the program, the company will repurchase up to 23,434,121 shares at a price of $0.5256 per share, for CAD 12.32 million. The program is expected to be financed through the use of a portion of the company's existing cash reserves and the proceeds from the issuance of $5 million in term debt. The program is subject to regulatory and disinterested shareholder approval at a special meeting to be held on September 16, 2021. Board Change • Aug 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Wei Han was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 29
Second quarter 2021 earnings released: EPS CA$0.007 (vs CA$0.009 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CA$5.63m (down 5.4% from 2Q 2020). Net income: CA$266.4k (down 21% from 2Q 2020). Profit margin: 4.7% (down from 5.7% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Board Change • Jul 29
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Wei Han was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 21
First quarter 2021 earnings released: EPS CA$0.01 (vs CA$0.01 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2021 results: Revenue: CA$3.43m (down 50% from 1Q 2020). Net loss: CA$420.7k (down 191% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Reported Earnings • Apr 02
Full year 2020 earnings released: EPS CA$0.05 (vs CA$0.034 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CA$24.4m (up 18% from FY 2019). Net income: CA$2.09m (up CA$3.39m from FY 2019). Profit margin: 8.6% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Annonce • Jan 28
BIOREM Inc.(TSXV:BRM) dropped from S&P/TSX Venture Composite Index BIOREM Inc.(TSXV:BRM) dropped from S&P/TSX Venture Composite Index Is New 90 Day High Low • Jan 06
New 90-day high: CA$0.64 The company is up 80% from its price of CA$0.35 on 06 October 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Commercial Services industry, which is up 16% over the same period. Annonce • Dec 15
BIOREM Inc. Announces Research Project with City of New York to Control Release of Bioaerosols from Waste Water Treatment Facilities BIOREM Inc. announced a research project in collaboration with the City of New York to examine the efficacy of BIOREM's enhanced biological processes for the mitigation of odours and hazardous air pollutants from various wastewater treatment facilities under their operation. A key component of the research and demonstration project will be to look at the effectiveness of BIOREM's systems to reduce or eliminate the transmission of bioaerosols from these emissions. BIOREM has designed a dual-stage biological system specifically optimized to address the types of emissions anticipated from the various processes. The unit has been constructed and delivered to the first study location. The overall length of the research project is expected to last for one year. Is New 90 Day High Low • Dec 15
New 90-day high: CA$0.58 The company is up 71% from its price of CA$0.34 on 14 September 2020. The Canadian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Commercial Services industry, which is up 19% over the same period. Annonce • Dec 10
BIOREM Inc. Announces Successful Demonstration Projects Assessing Novel Biological Processes for the Mitigation of Industrial VOC Emissions BIOREM Inc. announced the successful completion of two research projects for the mitigation of volatile organic compounds from complex industrial gas emissions. Both projects were to assess and compare the efficacy of BIOREM's enhanced biological processes against legacy abatement technologies. Historically, thermal oxidation or chemical scrubbing has been utilized for mitigating complex industrial emissions. The high operating costs, safety concerns and generation of secondary contaminants all contribute to very large carbon footprints for these technologies. 
